valrubicin has been researched along with Carcinoma in Situ in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Gellhaus, PT; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Ryder, K; Slater, SJ; Smith, ND; Steinberg, GD; Strangman, NM | 1 |
| Dinney, CP; Greenberg, RE; Steinberg, GD | 1 |
| Lamb, HM; Onrust, SV | 1 |
| Bahnson, R; Brosman, S; Middleton, R; Steinberg, G; Wajsman, Z; Wehle, M | 1 |
| Erwin-Toth, P; Grossman, HB; Lamm, DL; Magar, R; Marchetti, A; Schellhammer, PF; Wang, L | 1 |
| Bahnson, R; Greenberg, RE; Gulfo, J; Israel, M; Patterson, AL; Sweatman, T; Wajsman, Z; Webber, D; Weems, L | 1 |
| Klotz, L | 1 |
| Kim, JC; Steinberg, GD | 1 |
| Alsikafi, NF; Kuznetsov, DD; O'Connor, RC; Steinberg, GD | 1 |
| Randall, S | 1 |
| Haisfield-Wolfe, ME | 1 |
4 review(s) available for valrubicin and Carcinoma in Situ
| Article | Year |
|---|---|
Valrubicin.
Topics: Administration, Intravesical; Animals; Carcinoma in Situ; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Humans; Lethal Dose 50; Urinary Bladder Neoplasms | 1999 |
Medical management of patients with refractory carcinoma in situ of the bladder.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Humans; Immunotherapy; Photochemotherapy; Urinary Bladder Neoplasms | 2001 |
Intravesical valrubicin in the treatment of carcinoma in situ of the bladder.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Guidelines as Topic; Humans; Molecular Structure; Urinary Bladder Neoplasms | 2001 |
Valrubicin: an alternative to radical cystectomy for carcinoma in situ of the bladder.
Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Cystectomy; Doxorubicin; Humans; Neoplasm Staging; Nursing Assessment; Urinary Bladder Neoplasms | 2001 |
3 trial(s) available for valrubicin and Carcinoma in Situ
| Article | Year |
|---|---|
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Failure; Urinary Bladder Neoplasms | 2000 |
Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin.
Topics: BCG Vaccine; Carcinoma in Situ; Costs and Cost Analysis; Cystectomy; Doxorubicin; Humans; Injections; Models, Economic; Urinary Bladder; Urinary Bladder Neoplasms | 2000 |
Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Humans; Male; Pilot Projects; Postoperative Complications; Salvage Therapy; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urination Disorders | 2000 |
6 other study(ies) available for valrubicin and Carcinoma in Situ
| Article | Year |
|---|---|
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Docetaxel; Doxorubicin; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms | 2022 |
Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
Topics: Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Humans; Male; Middle Aged; Time Factors; Urinary Bladder Neoplasms | 2011 |
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Topics: Abdominal Pain; Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Doxorubicin; Dysuria; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Treatment Failure; Urinary Bladder Neoplasms; Urinary Tract Infections | 2013 |
Valrubicin for bladder cancer.
Topics: Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Urinary Bladder Neoplasms | 1999 |
Re: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carcinoma in Situ; Cystectomy; Doxorubicin; Humans; Urinary Bladder Neoplasms | 2000 |
Drug handling questioned.
Topics: Antineoplastic Agents; Carcinoma in Situ; Doxorubicin; Humans; Medical Waste Disposal; Urinary Bladder Neoplasms | 2001 |